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A B S T R A C T
Official guidelines for the indications of conventional permanent pacing are being 
updated periodically as the indications evolve continually. Also nontraditional indica-
tions for pacing emerge, such as marked first-degree AV block, malignant vasovagal 
syncope, obstructive hypertrophic cardiomyopathy, and paroxysmal atrial fibrillation. 
A critical review and analysis of these indications is undertaken in this review article.
I N T R O D U C T I O N
The indications for conventional pacing evolve continually with periodic upgrading 
of the well-known ACC/AHA/NASPE guidelines1 and the development of nontradi-
tional indications such as marked first-degree AV block, malignant vasovagal syncope, 
obstructive hypertrophic cardiomyopathy, and paroxysmal atrial fibrillation.1-4 Rapid 
advances in pacemaker technology have provided improved systems to match the needs 
of patients in the aforementioned special situations.
2 0 0 2  A C C / A H A / N A S P E  G U I D E l I N E S
C O m P l E T E  AV  B l O C k
The 2002 ACC/AHA/NASPE guidelines designate, like the previous ACC/AHA 
recommendations, asymptomatic complete AV block (in the absence of co-morbidity) 
with ventricular escape rates >40 bpm as a class II indication for pacing. The rate 
criterion of >40 bpm is arbitrary and unnecessary. It is not the escape rate that is 
critical to stability, but rather the site of origin of the escape rhythm (junctional or 
ventricular). Rate instability may not be predictable or obvious. Irreversible acquired 
complete AV block should be a class I indication for pacing.2
T y P E  I  S E C O N D - D E G R E E  AV  B l O C k
The 2002 ACC/AHA/NASPE guidelines state that type I second-degree AV block 
is usually due to delay in the AV node irrespective of QRS width.1 Type I second-
degree AV block with bundle branch block (far less common than narrow QRS type 
I block) must not be automatically labeled as AV nodal on the basis of this statement. 
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AbbreviAtions
ACC = American College of Cardiology
AHA = American Heart Association
AV = atrioventricular
AVI = AV interval
ICD = implantable cardioverter 
defibrillator
LPRI = long PR interval
LV = left ventric-le(-ular)
LVOT = left ventricular outflow tract
MI = myocardial infarction
NASPE = North American Society of 
Pacing & Electrophysiology (now 
renamed: Heart Rhythm Society-HRS)
OHCM = obstructive hypertrophic 
cardiomyopathy
PVARP = post-ventricular atrial 
refractory period
RV = right ventricle
Presented in part at “Cardiology Update 2004”, International Cardiology Symposium of Evagelismos General Hospital of Athens, Athens, 
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With associated bundle branch block, type I block occurs 
in the His-Purkinje system in 60-70% of cases.5 Infranodal 
type I block carries a poor prognosis with a substantial risk 
of progression to complete heart block.5 Indeed, it is widely 
believed that type I and type II infranodal block carry the 
same prognosis. Consequently, most authorities recommend 
an electrophysiological study in asymptomatic patients with 
type I block and bundle branch block to determine the site 
of block.5 The 2002 ACC/AHA/NASPE guidelines do not 
fully endorse this concept in the recommendation that “type 
I second-degree AV block at intra- or infra-His levels found 
at electrophysiology study performed for other indications” is 
a class IIa indication for pacing.1 A more aggressive approach 
to this problem would be preferable because type I second-
degree AV block in the His-Purkinje system represents diffuse 
conduction system disease and should be a class I indication 
for permanent pacing even in an asymptomatic patient.
T y P E  I I  S E C O N D - D E G R E E  AV  B l O C k
The definition of type II second-degree AV block contin-
ues to be problematic over 35 years since the advent of His 
bundle recordings and invasive cardiac electrophysiology.6 
In the 1998 ACC/AHA guidelines,7 the definition of type II 
block was incomplete and subject to misinterpretation (“no 
progressive prolongation of the PR intervals before a blocked 
beat”). Note that “beat” was singular and conformed to the 
widely accepted criterion of a single blocked beat in the 
definition of type II block.6,8,9 The 2002 ACC/AHA/NASPE 
guidelines state that “type II second-degree AV block is char-
acterized by fixed PR intervals before and after the blocked 
beats.” The pleural “beats” implies block of more than one 
beat that may create confusion with “advanced AV block” 
defined in the guidelines as block of 2 or more P waves. The 
2002 ACC/AHA/NASPE guidelines as in the past, fail to 
mention the importance of a stable sinus rate in the diagnosis 
of type II second-degree AV block (Stability of the sinus rate 
is an important diagnostic criterion of type II block because 
a vagal surge can cause simultaneous sinus slowing and AV 
nodal block, generally a benign condition that can superficially 
resemble type II block.6,10 Furthermore, vagally-induced AV 
block may occasionally exhibit an unchanged PR interval after 
a single blocked beat. It is also important to remember that 
when the PR interval after a single blocked impulse is shorter 
or the P wave is missing (if preempted by an escape complex), 
the diagnosis of type II block cannot be made regardless of 
the constancy of all the PR intervals before the single noncon-
ducted P wave.6 Such an arrangement should be considered 
as unclassifiable in terms of type II block.6
The 2002 ACC/AHA/NASPE guidelines introduced a 
new classification of type II second-degree AV block: wide 
QRS type II block (which makes up 65-80 % of type II blocks) 
with a class I indication for pacing and narrow QRS type II 
block with a class II indication for permanent pacing.1 This 
differentiation is strange because there is no evidence that 
narrow QRS type II block is less serious than wide QRS type 
II block. The statement that “type II block is usually infranodal 
especially when the QRS is wide” may be the basis for this 
potentially misleading distinction. Type II block according to 
the strict definition is always infranodal and should be a class 
I indication regardless of QRS duration, symptoms or whether 
it is paroxysmal or chronic.2,6
I N T R AV E N T R I C U l A R  C O N D U C T I O N  B l O C k S
The 2002 ACC/AHA/NASPE guidelines do not fully 
address certain types of AV block that require provoca-
tive maneuvers for diagnosis. Most of these situations like 
non-physiologic second- or third-degree His-Purkinje block 
induced by a “stress test” (that involves gradually increasing 
the rate of atrial pacing) should be class I indications irrespec-
tive of symptoms.11 These conditions include: 1) The “fatigue” 
phenomenon in the His-Purkinje system induced only after 
abrupt cessation of rapid ventricular pacing (with or without 
the concomitant administration of a type IA antiarrhythmic 
agent in selected cases).12,13 This challenge is usually per-
formed after an unremarkable response to an atrial pacing 
“stress test.” 2. Bradycardia-dependent (phase 4) block (not 
bradycardia-associated as in vagally-induced AV block). Phase 
4 block is always infranodal and can be diagnosed with His 
bundle recordings and pauses following electrically-induced 
atrial or ventricular premature beats.14
A C U T E  m y O C A R D I A l  I N fA R C T I O N
The ACC/AHA/NASPE 2002 guidelines advocate “per-
sistent and symptomatic AV block” after acute myocardial 
infarction (MI) as a class I indication for pacing.1 This vague 
statement ignores the simple fact that any form of AV block in 
acute MI can be symptomatic before it resolves completely.
The 2002 ACC/AHA/NASPE guidelines recommend that 
an electrophysiological study may be necessary if the site of 
block is uncertain in transient advanced (second- or third-
degree) AV block and bundle branch block, a possible class I 
indication. However, the guidelines provide no information 
how to interpret the data from an electrophysiological study in 
the decision process to implant a permanent pacemaker.2
The 2002 ACC/AHA/NASPE guidelines continue to 
classify “persistent AV nodal block” as a class II indication 
without defining the term “persistent.” The latitude of this 
recommendation may promote the unnecessary implantation 
of pacemakers in patients with inferior MI and narrow QRS 
AV block where permanent pacing is almost never required.15 
The term “persistent” has been interpreted by some workers 
to mean 14-16 days, a cut-off point that seems satisfactory. 15 
On the basis of the 14-16 day criterion the need for permanent 
pacing in survivors of inferior MI who develop second- and/or 
third-degree AV block should not exceed 1-2% of the entire 
AV block group whether or not they are treated with throm-
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bolytics or primary angioplasty.
S P E C I A l  S I T U A T I O N S
f I R S T- D E G R E E  AV  B l O C k
The hemodynamic disturbance produced by marked first-
degree AV block (>0.30 sec) has been called the “pacemaker 
syndrome without a pacemaker” because inadequate timing of 
atrial and ventricular systole forms the basis of the pacemaker 
syndrome.16,17 Both sinus rhythm with a very long PR interval 
and VVI pacing with retrograde ventriculoatrial conduction 
share the same pathophysiology with P waves too close to 
the preceding ventricular complexes (Figures 1, 2). The 2002 
ACC/AHA/NASPE guidelines for pacemaker implantation 
state that “first- or second-degree AV block with symptoms 
similar to pacemaker syndrome” constitutes a class IIa indica-
tion.1 This recommendation was logically extended in the latest 
version to patients with type I second-degree AV block (even 
without bradycardia) who experience hemodynamic compro-
mise due to loss of AV synchrony.1,2 This recommendation 
for a dual chamber pacemaker with a more physiologic AV 
interval, applies primarily to patients with well-preserved left 
ventricular (LV) function. Patients with a poor LV fraction 
≤35% should be considered for biventricular DDDR pacing 
especially in the setting of congestive heart failure. Invasive 
hemodynamic measurements may be helpful in questionable 
cases but need not be routine in the decision process to implant 
a pacemaker.1 The diagnosis is obvious when the long PR in-
terval does not shorten during an exercise test in association 
with effort intolerance and dyspnea.
A DDD pacemaker can restore a relatively normal AV 
interval, but it necessarily produces a paced sequence from 
the right ventricle (RV) which produces LV desynchronization 
that adversely affects cardiac hemodynamics, and LV myocar-
dial perfusion and function.18 Thus, in the individual patient 
with a long PR interval (LPRI) as an isolated abnormality, 
the clinician must decide whether there will be a net benefit 
provided by 2 opposing factors: a positive effect from AV delay 
optimization with a shorter AV delay and a negative inotropic 
effect produced by pacing- induced aberrant ventricular de-
polarization.18 This determination can sometimes be made 
clinically and noninvasively but a hemodynamic study with 
temporary pacing may be required in selected cases (Fig. 2). In 
this respect, Iliev et al.19 compared the AAI and DDD modes 
in patients with sick sinus syndrome (DDD pacemakers) and 
native but long AV conduction in otherwise normal hearts. At 
a pacing rate of 70 ppm at rest, there was no overall differ-
ence in the aortic flow time velocity integral (which reflects 
cardiac output) during AAI and DDD pacing. However when 
the patients were divided according to the AV interval (AVI), 
those with AVI <270 ms showed a higher aortic flow velocity 
integral during AAI pacing. When the AVI was >270 ms, the 
aortic flow velocity integral was higher during DDD pacing. 
Thus during DDD pacing the increments in cardiac output 
were greater with the longer native AV intervals. Conversely 
with a normal or near normal PR interval, a higher cardiac 
output was found during AAI pacing with a conducted QRS 
complex and spontaneous ventricular depolarization. Not 
surprisingly these workers found that at a pacing rate of 90 
ppm, DDD was superior to AAI pacing. These data provide 
an important guideline in the management of patients with 
LPRI in that the hemodynamic improvement with pacing 
outweighs the negative impact on LV function when the PR 
interval >0.28 sec. Despite these hemodynamic considerations 
the long-term consequences of RV pacing on LV function in 
the LPRI syndrome are unknown.
Pacemaker programming
An increase in the sinus rate coupled with a long PR 
interval can push the P wave continually into the postven-
tricular atrial refractory period (PVARP) of a dual chamber 
pacemaker where it cannot be tracked.20 This form of func-
tional atrial undersensing can often be corrected or reduced 
by shortening the PVARP and AV delay. A relatively short 
PVARP (that would otherwise predispose to endless loop 
tachycardia) can often be used in the LPRI syndrome because 
retrograde VA block is common in these patients. In refrac-
tory cases of functional undersensing, AV junctional ablation 
should be considered. A recently developed algorithm used in 
cardiac resynchronization devices could be useful in the treat-
ment of functional atrial undersensing in patients with LPRI 
syndrome. This algorithm restores 1:1 atrial tracking (provided 
the rate is slower than the programmed upper rate) by detect-
ing the atrial event in the PVARP, whereupon it temporarily 
shortens the PVARP and permits sensing of the P wave outside 
the PVARP to promote the return of atrial tracking.
fIGURE 1. Surface ECG and intracardiac recording from a pa-
tient with symptomatic marked first-degree AV block. RA = 
high right atrial electrogram, HBE= electrogram at site of His 
bundle recording. Note the sequence of atrial activation (RA to 
HBE) is consistent with sinus rhythm and rules out retrograde 
atrial activation. The AH interval is markedly prolonged.
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V A S O V A G A l  S y N C O P E
Most patients with vasovagal syncope develop varying 
degrees of bradycardia during syncope. There is always a 
variable degree of vasodilatation. The value of pacing has 
therefore been questioned because vasodilatation often ac-
companies bradycardia at the time of fainting. In about 30% of 
the patients, the predominant manifestation is a vasodepressor 
reaction with hypotension without significant bradycardia. 
Pacing is obviously inappropriate in this group.
The results of observational nonrandomized studies 
suggest that dual chamber pacing may benefit patients with 
vasovagal syncope often in combination with drug therapy 21,22 
single chamber (atrial or ventricular) pacemakers and dual 
chamber devices without atrial stimulation are contraindi-
cated because they do not fully address the pathophysiology. 
Three randomized unblinded trials (2 multicenter controlled 
trials and one comparing beta-blocker therapy with pacing) 
suggested the efficacy of dual chamber pacing in a highly 
selected patient population with predominant cardioinhibi-
tory syncope.23-25 However, the fourth and last trial (2003) 
which was randomized and blinded (VPS II) showed no real 
benefit of pacing.26 The study compared DDD (rate-drop 
response) vs ODO (sensing only). After 6 months, there was 
a trend towards pacing increasing the time to recurrence with 
a relative risk reduction of 30% which was not quite statisti-
cally significant (data presented in 2004 at the Heart Rhythm 
Society meeting indicated the same results after 1 year). At 
this juncture, pacing remains controversial and certainly ca-
pable of providing a placebo effect. The role of pacing needs 
further investigation because the VPS II study included only 
100 patients, the eligibility criteria did not demand the same 
degree of bradycardia as in other randomized studies and the 
follow-up was relatively short.
Pacing seems to work in selected patients but is it worth 
it? Dual chamber pacing should not be first-line therapy for 
vasovagal syncope because many patients respond to drug 
therapy and/or training measures. The selection of candidates 
for pacing therapy is still unclear but it should be carefully 
considered in highly symptomatic patients with demonstra-
ble (relative) bradycardia refractory if a reasonable course 
of medical therapy (at least 3 medication attempts) fails to 
prevent syncope. It is difficult to recommend a device (no-
return therapy) for the following reasons: 1. Most patients 
are young and otherwise healthy. 2. The ability to discern the 
relative contributions of cardioinhibitory and vasodepressor 
features may be difficult. 3. Spontaneous vasovagal events 
may not always exhibit the same pathophysiologic features in 
a given individual and 4. Syncopal episodes may be clustered 
and sporadic. The decision to implant a pacemaker is easier in 
the older population. The 2002 ACC/AHA/NASPE guidelines 
for pacemaker implantation now recommend pacing carefully 
prescribed on the basis of tilt table testing as a class IIa indi-
cation, an unjustified promotion from a class IIb indication 
in the 1998 ACC/AHA guidelines.1,7 However a conservative 
approach is wise because of the basically benign course of the 
fIGURE 2. Same patient as Figure 1. A. Pulmonary capillary wedge pressure shows large cannon waves during sinus rhythm with a 
very long PR interval (Scale 0-40 mmHg). B. Note the normal pulmonary capillary wedge pressure after temporary dual chamber 
pacing with a physiologic AV delay (Scale 0-40 mm Hg).
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disease. The role of pacing is therefore likely to remain small 
and used only in highly selected patients: those with frequent 
episodes of syncope, in the setting of poor quality-of-life, risk 
of injury, occupational hazard, and in the absence of warn-
ing.27 The implantation rate should be less than 0.5-1% of all 
the patients with this condition though it is unsurprising that 
about 2% of patients eventually referred to tertiary centers 
receive pacemakers.
Pacing attenuates the hemodynamic manifestations of 
vasovagal syncope and attenuates the fall in blood pressure. 
A more gradual drop in blood pressure during the attacks can 
be perceived thereby enabling the patient to take appropriate 
measures: lying down or stop driving a car. In patients with 
significant bradycardia during syncope, pacing may reduce 
or prevent episodes of syncope and significantly prolong 
the time from onset of symptoms to loss of consciousness. 
Thus dual chamber pacing with appropriate algorithms for 
vasovagal syncope can retard the appearance of symptoms. 
There is some evidence that a hysteresis rate-drop algorithm is 
superior to conventional pacing.22 This algorithm works with a 
programmable heart-rate change-time duration “window” to 
quickly detect abrupt cardiac slowing (diagnosis) whereupon 
it activates a short period of selectable high rate pacing for a 
programmed duration (therapy). Pacemakers are being devel-
oped with special sensors to detect vasovagal pathophysiology 
in its early phase so that pacing therapy can begin earlier than 
with present devices that detect only bradycardia. The results 
of the randomized trials27 may reflect the fact that we may be 
presently pacing the wrong way and that better technology and 
an earlier response may produce better results.
O B S T R U C T I V E  H y P E R T R O P H I C 
C A R D I O m y O P A T H y
Many observational studies have suggested that dual 
chamber pacing can be effective therapy for symptomatic 
relief in patients with obstructive hypertrophic cardio-
myopathy (OHCM).28-32 Pacing reduces the LV outflow 
(LVOT) gradient by about 50% in most patients. However, 
data from controlled crossover randomized trials (that 
involved only 3 relatively small studies discussed below) 
are far less impressive and even controversial.33-35 In the 
European Pacing In Hypertrophic Cardiomyopathy study 
(PIC study), 83 patients with OHCM (refractory or intolerant 
to drug therapy) and a resting LVOT gradient >30 mmHg 
underwent a randomized, cross-over study between AAI (at 
30 ppm) and DDD pacing with short AV interval, each for 
a 12 week period.33 Seventy-nine of the 83 patients (95%) 
preferred DDD pacing. Subsequent follow-up of patients 
for one year showed that pacing was beneficial on pressure 
gradient and symptoms in 72 patients (87%).36 Subgroup 
analysis of the PIC data showed that improvement de-
pended upon age, with a marked improvement between 
the ages of 60 and 70 which was statistically significant 
compared to other decades.
On the other hand, the M-PATHY study, which rand-
omized 48 patients with resting LVOT 50 mmHg to receive 
3 months of DDD and 3 months of AAI pacing, showed that 
the symptoms were not improved but when the patients were 
unblinded and followed for an additional 6 months, patients 
in the DDD phase were symptomatically improved.34 This 
response suggests a strong placebo effect of pacing. In a sub-
group of 6 elderly patients (>65 years), more striking clinical 
improvement was noted. In a smaller study with a similar 
double-blind randomized crossover design (21 patients with 
19 completing the study), Nishimura et al35 showed that pacing 
produced no symptomatic response despite significant reduc-
tion of LVOT tract gradient when DDD pacing was compared 
to AAI backup pacing (30/min) an observation consistent with 
a placebo effect.
The mixed findings in the 3 randomized trials are difficult 
to explain. Observations by Linde et al suggest that improve-
ment with pacing is probably based on more than a placebo 
effect.37 OHCM is a complex heterogeneous disease with 
variable symptoms and gradients so that an intervention such 
as pacing is liable to produce variable results. Furthermore 
changes in exercise capacity and NYHA class are not neces-
sarily associated with a reduction in LVOT gradient.
The implantation of dual-chamber pacing is not primary 
therapy and should not be considered as replacement for 
drug therapy. Pacing should be weighed against the risk 
and efficacy of surgical left ventricular myectomy and 
percutaneous transcoronary septal myocardial ablation 
with ethanol injection into the first septal artery (chemical 
myectomy).38-40 There are no prospective randomized stud-
ies comparing pacing with other therapeutic strategies. The 
2002 ACC/AHA/NASPE guidelines for implantation of 
pacemakers list medically refractory symptomatic HOCM 
with significant resting or provoked LV outflow obstruction 
as a Class IIb indication seemingly based on data from 
observational reports with favorable results derived mostly 
from retrospective uncontrolled studies.1 The guidelines 
are vague on what constitutes a “significant resting or 
provoked gradient” in HOCM patients but they do say that 
patients with a resting gradient ≥30 mm Hg or a provoked 
LVOT gradient ≥50 mm Hg may derive the most benefit. 
Pacing is obviously indicated in patients who develop bradycar-
dia secondary to successful pharmacologic therapy. In patients 
without bradycardia, pacing for HOCM should be considered 
only in drug-refractory patients (especially the elderly) in 
whom surgical myomectomy (superior to pacing in symptom 
relief and gradient reduction according to a recent comparison 
study) is either unwise, contraindicated, rejected (or are not 
optimal candidates). Such patients should be warned of the 
uncertainty of acute or long-term improvement.
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PA C E m A k E R  P R O G R A m m I N G
A flexible dual chamber device and meticulous program-
ming are essential for successful outcome. The pacemaker 
must be programmed with a short AV interval to avoid sponta-
neous ventricular depolarization at all times. One must ensure 
complete ventricular capture at rest and on exercise without 
any evidence of ventricular fusion resulting from partial 
activation via the normal pathways.4 The optimal pacemaker 
AV delay should be determined under echo-Doppler control. 
An excessively short AV delay causes impaired LV filling and 
loss of the atrial contribution. A relatively long pacemaker AV 
delay defeats the very purpose of pacing. In some patients the 
PR interval is so short that the pacemaker cannot provide an 
hemodynamically beneficial AV delay shorter than the PR 
interval. Drugs may help by prolonging AV conduction. In 
refractory cases, the creation of complete AV block by radi-
ofrequency ablation of the AV junction permits the establish-
ment of pacemaker-controlled ventricular depolarization at 
all times and facilitates overall management.
fA I l U R E  O f  PA C I N G  T O  I m P R O V E  S y m P T O m S 
A N D  R E l I E V E  O B S T R U C T I O N
The commonest cause of failure to improve symptoms or 
reduce the LVOT gradient is inappropriate pacemaker pro-
gramming with the AV delay too short or too long.4,28,29 A poor 
response may be due to a proximal RV pacing lead instead of 
the most distal apical site. Other causes include an inadequate 
trial period (months may be required), mitral regurgitation 
(primary or unrelated to OHCM), aberrant papillary muscle 
obstructing the LVOT, mid-cavity obstuction, inappropriate 
drug therapy and atrial and ventricular arrhythmias. 29,30
m E C H A N I S m  O f  I m P R O V E m E N T  A N D  N A T U R A l 
H I S T O R y
Inverted LV activation and altered or paradoxical septal 
motion widens the LVOT in systole. This mechanism does 
not entirely explain the therapeutic benefit because there is 
a progressive reduction in the LVOT gradient with time.4,30 
Indeed some patients do not improve on a short-term basis 
but require several months or longer for optimal improvement. 
This suggests that factors other than altered septal motion, 
such as cellular and molecular modification of the myocardium 
account for the clinical improvement. The evidence for LV re-
modeling is controversial. The impact of pacing on the natural 
history and prevention of sudden death is unknown.
I N D I C A T I O N S  f O R  A  D U A l  C H A m B E R 
D E f I B R I l l A T O R
Pacing does not reduce mortality or sudden cardiac death. 
The question arises as to whether it would be preferable 
to implant a dual chamber defibrillator (with DDDR pac-
ing capability) in most or all patients in whom pacing is 
being considered because of OHCM patients are at risk 
of malignant ventricular tachyarrhythmias and sudden 
death. At this juncture a prophylactic defibrillator (ICD) 
should at least be considered in high risk patients (whether 
or not pacing is intended): family history of sudden death, 
recurrent syncope, abnormal blood pressure response to 
exercise, septal or LV thickness ≥30 mm, and Holter docu-
mented nonsustained ventricular tachycardia. In future 
genotyping might become an important marker in risk 
stratification.41-44 Atrial tachyarrhythmias often result in 
serious hemodynamic consequences and an ICD with atrial 
defibrillation capability would also be a consideration. 
ICDs often remain dormant for prolonged periods before 
discharge (up to 9 years) emphasizing the unpredictability 
of arrhythmic sudden death, the long risk period and the 
need for extended follow-up.45-47
C O N T R O l  O f  P A R O x y S m A l  A T R I A l 
f I B R I l l A T I O N
Conventional dual chamber and AAI pacing reduces 
the incidence of chronic atrial fibrillation compared to 
single chamber ventricular pacing in patients with sick sinus 
syndrome.48 The 1998 ACC/AHA guidelines for pacemaker 
implantation stated a class IIb for “prevention of sympto-
matic drug-refractory recurrent atrial fibrillation”.7 This vague 
statement was misleading and it has now been replaced by 
“prevention of symptomatic drug-refractory recurrent atrial 
fibrillation in patients with coexisting sinus node disease” also 
as a class IIb indication.1 This new recommendation reflects 
the lack of evidence that pacing can prevent atrial fibrillation 
in patients without bradycardia. The complexity of pacing in 
atrial fibrillation depends on many factors: presence of brady-
cardia, left atrial size, interatrial conduction delay, underly-
ing disease, substrate modification at precise sites, single or 
multiple algorithms addressing triggers, potentiation by drugs 
and the precise definition of endpoints.
Modification of the atrial fibrillation substrate by dual site 
atrial pacing or pacing from single unconventional sites (high 
atrial septum near Bachmann’s bundle or low atrial septum) 
can prevent atrial fibrillation in some patients with advanced 
interatrial conduction delay (P wave >120 ms).49-54 Pacing ap-
pears less likely to provide an additive effect in patients with 
bradycardia but no interatrial conduction delay. The results 
are so far unimpressive and need to be confirmed in large-
scale trials.55,56 Furthermore, it is impossible to predict which 
patients will from these pacing modalities. When it works, pac-
ing improves the atrial activation sequence and reduces atrial 
asynchrony related to slow conduction.57,58 New pacemakers 
with sophisticated algorithms (delivering either dynamic over-
drive suppression without a substantial increase in the pacing 
rate or reacting to atrial premature beats) designed to target 
potential triggers of atrial fibrillation are being investigated 
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for the prevention of atrial fibrillation mostly in patients with 
antibradycardia pacemakers.57-59 Preliminary evidence sug-
gests that dynamic overdrive suppression provide a modest 
benefit by reducing atrial fibrillation burden in patients with 
conventional antibradycardia devices but the effect may be 
attenuated by frequent ventricular pacing.59,60 Many other 
complex algorithms are being investigated and a combina-
tion of several algorithms may ultimately prove more useful 
than a single one.57,58 Finally, antitachycardia pacemakers are 
capable of terminating organized atrial tachyarrhythmias that 
predispose to atrial fibrillation.61 All in all, the control of 
atrial fibrillation is difficult and often requires tailoring the 
treatment for individual patients employing so-called hybrid 
therapy with 2 or 3 strategies in the same patient, bearing in 
mind that pacing may potentiate the effect of antiarrhythmic 
therapy. Pacing should not replace pulmonary vein ablation 
in suitable candidates.
P A C I N G  f O R  S l E E P  A P N E A
Sleep apnea is a common medical problem, and affects 
2-4% of the middle-aged population of the United States. 
During apneic episodes there is a high incidence of asymp-
tomatic cardiac arrhythmias amenable to treatment. As the 
patients are asleep, these arrhythmias are asymptomatic. 
Recent observations suggest that pacemakers with minute-
ventilation sensors can make the diagnosis of sleep apnea 
in patients with congestive heart failure (CHF). In a recent 
publication, Garrigue et al62 reported that pacing may reduce 
the incidence of apnea/hypopnea episodes. The patients were 
randomized to AAI pacing at >15 bpm over the nocturnal 
rate, or to VVI pacing at 40 bpm, each for 1 day. There was a 
significant reduction from 9 to 3 episodes/hour after pacing 
without changing the sleeping duration nor the overall pacing 
rate. So far, these observations have not yet been confirmed in 
follow-up studies.63-65 No pacemaker has yet been implanted 
primarily for the treatment of sleep apnea but ongoing trials 
are evaluating this potential therapy in patients with sleep 
apnea who otherwise require antibradycardia pacing.
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